1. Q32 Bio will participate in two investor conferences in March 2025. 2. Management will present at TD Cowen and Leerink Partners events. 3. Focus is on bempikibart, an anti-IL-7Rα antibody in Phase 2 trials. 4. Webcasts of the presentations will be available on Q32 Bio's website. 5. Company targets autoimmune and inflammatory diseases with its therapies.
Participation in investor conferences often leads to increased visibility and investor interest. Historical instances show stocks often rise post-conference with positive sentiment.
The announcements can attract investor attention and potentially raise stock value. Increased discussions around bempikibart could positively shift market sentiment.
The upcoming investor events are immediate catalysts, likely affecting stock price soon.
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March:
Date: Wednesday, March 5, 2025
Presentation Time: 11:50 a.m. E.T.
Location: Boston, MA
Date: Tuesday, March 11, 2025
Fireside Chat Presentation Time: 11:20 a.m. E.T.
Location: Miami Beach, FL
A webcast of the presentations will be available on the Events and Presentations page of Q32 Bio's website at www.Q32Bio.com. Archived replays will be available for 90 days following the event.
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investors: Brendan Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
[email protected]
SOURCE Q32 Bio